USRE50563E1 - Use of an all-D-pentapeptide chemokine antagonist to reduce opioid dose in a person with pain - Google Patents

Use of an all-D-pentapeptide chemokine antagonist to reduce opioid dose in a person with pain

Info

Publication number
USRE50563E1
USRE50563E1 US17/701,974 US202217701974A USRE50563E US RE50563 E1 USRE50563 E1 US RE50563E1 US 202217701974 A US202217701974 A US 202217701974A US RE50563 E USRE50563 E US RE50563E
Authority
US
United States
Prior art keywords
thr
seq
ser
asn
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
US17/701,974
Inventor
Michael R. Ruff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Creative Bio Peptides Inc
Original Assignee
Creative Bio Peptides Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/177,344 external-priority patent/US10624945B2/en
Application filed by Creative Bio Peptides Inc filed Critical Creative Bio Peptides Inc
Priority to US17/701,974 priority Critical patent/USRE50563E1/en
Assigned to CREATIVE BIO-PEPTIDES, INC. reassignment CREATIVE BIO-PEPTIDES, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: RUFF, MICHAEL R.
Assigned to CREATIVE BIO-PEPTIDES, INC. reassignment CREATIVE BIO-PEPTIDES, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: RUFF, MICHAEL R.
Application granted granted Critical
Publication of USRE50563E1 publication Critical patent/USRE50563E1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods

Definitions

  • the most potent and effective drugs are the opioid analgesics, they are accompanied by a number of serious adverse effects, and they are not very effective in approximately half of the cases of chronic pain.
  • Chemokines desensitize opiate receptors and thereby enhance the perception of pain (Szabo, 2002, Chen, 2007). These findings provide a possible explanation for why opioids are relatively ineffective in inflammatory pain. Chemokines are released during inflammation, and they block the signaling of opioid receptors by a process of heterologous desensitization. From the data above, the hypothesis was formulated that a chemokine receptor antagonist (CRA), given with a suboptimal dose of morphine, will restore opioid analgesic efficacy by blocking the cognate chemokine ligand from binding to its receptor and desensitizing the opioid receptor.
  • CRA chemokine receptor antagonist
  • Painful diabetic neuropathy is a common complication of diabetes which adversely affects patients' daily life and represents a major public health problem. Although this painful signal is believed to originate in the peripheral nervous system, the precise cellular mechanisms of chronic pain associated with PDN remain poorly understood.
  • inflammation is also engaged in the pathogenesis of diabetic neuropathic pain, then 1) infiltration of immune cells in damaged nerves and/or activation of spinal microglia should coincide with the development of pain; 2) inhibiting inflammatory response in the peripheral and/or the central nervous system should reduce chronic pain.
  • CCL2 and CCL3 are two chemokines well known in mediating immune cell trafficking and immune response in the context of neuropathic pain.
  • Oral administration of RAP-103, a CCR2/CCR5 dual receptor antagonist for 7 days inhibited PDN associated inflammation by reducing significantly all examined inflammatory mediators.
  • the effect of RAP-103 is more pronounced at peripheral nerves.
  • FIGS. 1 A-B RAP103 reversed mechanical allodynia in rats with neuropathic pain.
  • FIGS. 2 A-B RAP103 reversed cold allodynia in rats with neuropathic pain.
  • FIGS. 3 A-F RAP103 (0.5 mg/kg, for 7 days, p.o.) significantly inhibited inflammation in the sciatic nerves of STZ rats
  • FIG. 4 RAP103 potentiates morphine analgesia in an animal model of post-surgical pain.
  • FIG. 5 Dose response curves of morphine alone compared to morphine plus RAP-103.
  • RAP-103 also referred to as R103
  • R103 0.5.-0.02 mg/Kg b.w., daily, for 7 days
  • chemokines reduce opioid efficacy
  • chemokine receptor antagonist like R103 (all-D-TTNYT), or related all-D-pentapeptides of the list below
  • R103 all-D-TTNYT
  • neuropathic pain to include back pain, post-surgical pain, neuropathic pain, cancer pain, pain from injury or trauma etc.
  • the effective human doses suggested by these animal studies would be 0.01 to 2 mg/Kg/day.
  • the peptides may be dosed as an oral pill, suspension, liquid, or by IV and subcutaneous injections to achieve pain control with decreased concomitant opioid use.
  • Some examples of other useful CRA antagonists that can reduce opioid dose or use are Maraviroc (a CCR5 antagonist) or AMD3100 (a CXCR4 antagonist).
  • the drug was prepared by dissolving 5 mg RAP103 in 50 ml autoclaved H 2 O at room temperature, which made up an initial concentration at 0.1 mg/ml. This source drug solution was prepared freshly for each experiment and it was kept for 8 days (duration of one experiment) at room temperature. Appropriate concentration for each dose was adjusted accordingly.
  • R103 all-D-TTNYT
  • a drug which acts directly on CCR5 and CCR3 chemokine receptors can reverse already established neuropathic hypersensitivity in diabetic rats
  • autoclaved water or R103 (0.004, 0.02, 0.1 or 0.5 mg/kg b.w.) was administered daily by oral gavage to rats who exhibited stable mechanical and cold allodynia.
  • Rats were habituated to the testing environment daily for at least two days before the experiments started. All animals were assessed for mechanical allodynia and cold allodynia of both hind paws before (behavioral baseline values before STZ injection) and once a week after diabetes induction until they exhibited stable hypersensitive states (before RAP103 treatment), where the treatment with RAP103 started. Assessment on the effects of RAP103 on mechanical and cold allodynia was performed between 2-4 hours following the drug administration.
  • mice Male, Sprague-Dawley rats (210-250 g) were purchased from Taconic Biosciences and acclimated in the animal house for a week before initiation of experiments. At the beginning of testing, 2 days prior to surgery, rats were placed into individual transparent cubicles with a wire mesh floor for an hour a day, to acclimate them to the testing chambers.
  • Paw withdrawal thresholds were measured using a series of von Frey filaments (North Coast Medical, Inc., Gilroy, Calif.), with gradually increasing logarithmic bending forces (equivalent to 2, 4, 6, 8, 10, 15, 26, and 60 g force). The filaments were applied to the plantar side of each hind paw in an ascending matter. Each filament was tested five consecutive times a few seconds apart. A positive response was defined as quick withdrawal or paw flinching after the application of a filament.
  • RAP-103 a CCR2/CCR5/CCR8 antagonist was tested for analgesic capacity.
  • RAP-103 was supplied as a powder, and was reconstituted in sterile, pyrogen-free water. Solutions were prepared and kept frozen until use. On the day of the experiment, solutions were thawed and kept on ice until they were injected into rats. Rats were injected i.p., 25 min post-surgery. Control animals received water (vehicle). Morphine sulfate was dissolved in pyrogen-free saline and injected s.c. in the dorsal flank at 25 min post-surgery.
  • dose response curves are shown for morphine alone and for morphine plus RAP-103 (0.5 mg/kg) for ability to reverse mechanical allodynia, a measure of pain sensitivity.
  • the ED 50 values were calculated from the graphic dose-response curves. As shown, the ED 50 for morphine was shifted to the left by about 2-fold by the addition of RAP-103.
  • the ability of RAP-103 to potentiate opioid efficacy suggests further uses of RAP-103, and the related peptides of the invention, to be novel treatments for addictions in general, and opioid use disorders in particular.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A method of treatment of pain in a person with a D peptide chemokine receptor antagonist (CRA), and a pharmaceutically acceptable carrier is disclosed. Because chemokines desensitize opiate receptors and enhance the perception of pain said D-peptide CRA, given with a suboptimal dose of an opioid, such as morphine, will restore opioid analgesic efficacy by blocking the cognate chemokine ligand from binding to its receptor and desensitizing the opioid receptor. This strategy of combining a suboptimal dose of morphine with a CRA enhances the potency of morphine, permitting use of lower doses of morphine to obtain equivalent and near maximal analgesia. Lower morphine (opioid) doses have less risk of adverse effects, and potentially also of development of tolerance and dependence.

Description

CROSS REFERENCE TO RELATED APPLICATIONS
This application is a reissue application of U.S. application Ser. No. 16/177,344, filed Oct. 31, 2018, now U.S. Pat. No. 10,624,945, issued Apr. 21, 2020, which claims the benefit of U.S. Provisional Application No. 62/579,545, filed Oct. 31, 2017, and is co-pending with reissue applications, U.S. application Ser. No. 17/698,065, filed Mar. 18, 2022, U.S. application Ser. No. 17/869,925, filed Jul. 21, 2022, and U.S. application Ser. No. 19/213,362, filed May 20, 2025, the disclosures of which are incorporated herein by reference in their entirety.
BACKGROUND
The opioid epidemic is one of the most urgent health emergencies in our country today. Drug overdose is now the leading cause of death for Americans under 50. In 2017, the number of Americans who will die from drug overdose will be roughly the same as the number of Americans who died in the Vietnam, Iraq, and Afghanistan wars combined. Families are at risk due to the parents' addiction. Hundreds of millions of opioid painkillers are given out each year in the U.S. Medically sanctioned opioid prescriptions, such as in post-surgical pain, are often a gateway to addiction. Reduced opioid need would reduce addiction risks.
Severe pain, especially chronic pain, is frequently accompanied by inflammation. Although the most potent and effective drugs are the opioid analgesics, they are accompanied by a number of serious adverse effects, and they are not very effective in approximately half of the cases of chronic pain.
Chemokines desensitize opiate receptors and thereby enhance the perception of pain (Szabo, 2002, Chen, 2007). These findings provide a possible explanation for why opioids are relatively ineffective in inflammatory pain. Chemokines are released during inflammation, and they block the signaling of opioid receptors by a process of heterologous desensitization. From the data above, the hypothesis was formulated that a chemokine receptor antagonist (CRA), given with a suboptimal dose of morphine, will restore opioid analgesic efficacy by blocking the cognate chemokine ligand from binding to its receptor and desensitizing the opioid receptor.
Because opioids are used in the management of diabetic neuropathic pain (Patil, 2015). we determined the efficacy of a small peptide chemokine receptor antagonist RAP-103 (all-D-TTNYT) to block pain in a model of diabetic neuropathy.
Painful diabetic neuropathy (PDN) is a common complication of diabetes which adversely affects patients' daily life and represents a major public health problem. Although this painful signal is believed to originate in the peripheral nervous system, the precise cellular mechanisms of chronic pain associated with PDN remain poorly understood. Inspired by the critical contribution of inflammation in injury models of neuropathic pain, here we reasoned that if inflammation is also engaged in the pathogenesis of diabetic neuropathic pain, then 1) infiltration of immune cells in damaged nerves and/or activation of spinal microglia should coincide with the development of pain; 2) inhibiting inflammatory response in the peripheral and/or the central nervous system should reduce chronic pain. To test the hypothesis, we first used behavioral and molecular/cellular approaches to explore chronic pain development and inflammatory reaction in Streptozotocin (STZ) induced diabetic rats. Our results showed that following the induction of diabetes, rats exhibited persistent mechanical and cold allodynia (up to five months post-induction). The levels of inflammatory molecules, including cytokines, IL1β, TNFα; chemokines CCL2, CCL3; and chemokines receptors CCR2 and CCR5 were dramatically increased in sciatic nerves and RAP-103 lowered them (FIG. 3 ). Microglia in the spinal cord dorsal horns became activated with hypertrophic morphology and an increase in microglial cell number. CCL2 and CCL3 are two chemokines well known in mediating immune cell trafficking and immune response in the context of neuropathic pain. Oral administration of RAP-103, a CCR2/CCR5 dual receptor antagonist for 7 days inhibited PDN associated inflammation by reducing significantly all examined inflammatory mediators. The effect of RAP-103 is more pronounced at peripheral nerves.
BRIEF DESCRIPTION OF THE FIGURES
FIGS. 1A-B. RAP103 reversed mechanical allodynia in rats with neuropathic pain.
FIGS. 2A-B. RAP103 reversed cold allodynia in rats with neuropathic pain.
FIGS. 3A-F. RAP103 (0.5 mg/kg, for 7 days, p.o.) significantly inhibited inflammation in the sciatic nerves of STZ rats
FIG. 4 . RAP103 potentiates morphine analgesia in an animal model of post-surgical pain.
FIG. 5 . Dose response curves of morphine alone compared to morphine plus RAP-103.
The treatment with RAP-103 (also referred to as R103) (0.5.-0.02 mg/Kg b.w., daily, for 7 days, resulted in a complete reversal of established hypersensitivity in STZ rats. The results suggest that functional antagonism of multiple chemokine receptors and innate immune receptors may be treatments and medicines for pain and inflammation. In view of the results showing that chemokines reduce opioid efficacy, these results suggest that administration of a chemokine receptor antagonist, like R103 (all-D-TTNYT), or related all-D-pentapeptides of the list below, will reduce pain by any cause, but especially inflammatory pain, to include back pain, post-surgical pain, neuropathic pain, cancer pain, pain from injury or trauma etc., and can reduce the amount or duration of opioid use in a person in need of pain control. The effective human doses suggested by these animal studies would be 0.01 to 2 mg/Kg/day. The peptides may be dosed as an oral pill, suspension, liquid, or by IV and subcutaneous injections to achieve pain control with decreased concomitant opioid use. Some examples of other useful CRA antagonists that can reduce opioid dose or use are Maraviroc (a CCR5 antagonist) or AMD3100 (a CXCR4 antagonist).
Materials and Methods
Induction and assessment of diabetes in rats Rats were fasted overnight and received a single intraperitoneal injection of streptozotocin (60 mg/kg, Sigma-Aldrich) in citrate buffer (pH 4.5) to induce type I diabetes. The induction of diabetes was confirmed 72 h after streptozotocin injection by measurement of blood glucose levels using Contour® blood glucose diagnostic kit (Bayer HealthCare, Canada). Body weight and blood glucose levels were measured before and 3 days after streptozotocin injection, once a week for three weeks after diabetes induction. Only rats having blood glucose concentration consistently higher than 300 mg/dl were used for the present study.
Drug Preparations:
The drug was prepared by dissolving 5 mg RAP103 in 50 ml autoclaved H2O at room temperature, which made up an initial concentration at 0.1 mg/ml. This source drug solution was prepared freshly for each experiment and it was kept for 8 days (duration of one experiment) at room temperature. Appropriate concentration for each dose was adjusted accordingly.
Treatment Paradigms
To investigate whether R103 (all-D-TTNYT), a drug which acts directly on CCR5 and CCR3 chemokine receptors can reverse already established neuropathic hypersensitivity in diabetic rats, autoclaved water or R103 (0.004, 0.02, 0.1 or 0.5 mg/kg b.w.) was administered daily by oral gavage to rats who exhibited stable mechanical and cold allodynia. The treatment lasted for 8 days (n=5 for H2O and n=7 for RAP-103/each dose).
Assessment of Pain Sensitivity
Tactile Allodynia
Mechanical sensitivity was assessed using calibrated von Frey hairs as described by Chaplan et al (1994). Animals were placed in Plexiglas boxes on an elevated metal mesh floor and allowed 60 min for habituation before testing. A series of von Frey filaments with logarithmically incrementing stiffness (Stoelting) was applied perpendicular to the mid-plantar region of the hind paw. The 50% paw withdrawal threshold was determined using Dixon's up-down method as previously described (Dixon, 1980). Withdrawal thresholds of both paws were averaged as one single value per animal.
Cold Allodynia
The same apparatus (Plexiglas cylinder resting on a mesh floor) as the one described above for the von Frey test was used. Rats were allowed adapting to the testing environment for at least 10 min. Then, a drop (50
Figure USRE050563-20250902-P00001
l) of acetone was applied with a glass syringe fitted with a blunted needle at the center of the plantar face of a hind paw. Acetone was applied alternately twice to each hind paw, with 5 min between each successive application. Responses were monitored during 1 min after acetone application and were graded according to a 4-point scale, as previously described by Flatters and Bennett (2004): 0, no response; 1, quick withdrawal, flick or stamp of the paw; 2, prolonged withdrawal or repeated flicking of the paw; 3, repeated flicking of the paw with persistent licking directed at the ventral side of the paw. Cumulative scores were then obtained by summing the four scores for each rat, the minimum score being 0 (no response to any of the four trials) and the maximum possible score being 12 (repeated flicking and licking of paws on each of the four trials).
Rats were habituated to the testing environment daily for at least two days before the experiments started. All animals were assessed for mechanical allodynia and cold allodynia of both hind paws before (behavioral baseline values before STZ injection) and once a week after diabetes induction until they exhibited stable hypersensitive states (before RAP103 treatment), where the treatment with RAP103 started. Assessment on the effects of RAP103 on mechanical and cold allodynia was performed between 2-4 hours following the drug administration.
Data Analysis
All data were presented as means±SEM. Statistical analysis was performed by two-way ANOVA followed by Bonferroni post-tests. The criterion for statistical significance was P<0.05.
Use of R103 to Reduce the Need for Opioids in the Treatment of Pain
Animals:
Male, Sprague-Dawley rats (210-250 g) were purchased from Taconic Biosciences and acclimated in the animal house for a week before initiation of experiments. At the beginning of testing, 2 days prior to surgery, rats were placed into individual transparent cubicles with a wire mesh floor for an hour a day, to acclimate them to the testing chambers.
Surgery:
On the day of surgery, rats were acclimated for 30 min in the chambers, and then their individual baseline values for mechanical allodynia were assessed. Paw withdrawal thresholds were measured using a series of von Frey filaments (North Coast Medical, Inc., Gilroy, Calif.), with gradually increasing logarithmic bending forces (equivalent to 2, 4, 6, 8, 10, 15, 26, and 60 g force). The filaments were applied to the plantar side of each hind paw in an ascending matter. Each filament was tested five consecutive times a few seconds apart. A positive response was defined as quick withdrawal or paw flinching after the application of a filament. Surgery was performed under isoflurane anesthesia (4% isoflurane for induction and 2.5% isoflurane for maintenance of anesthesia) using aseptic conditions. A 1 cm longitudinal incision (starting 0.5 cm from proximal edge of the heel and extending toward the toes) was made with a scalpel through skin and the fascia of the plantar side of the left hind paw. The plantaris muscle was exposed, elevated and incised longitudinally. Following bleeding control with gentle pressure, the skin was closed with two single interrupted sutures using 5-0 nylon. Animals were brought back to their individual chambers for mechanical allodynia testing. For kinetic assessment of pain, the time of surgery completion was designated as time 0. Paw withdrawal thresholds were recorded by a person blinded to the treatments at time points of 15, 30, 45, 60, 120, 240, and 360 min on the day of surgery, as well as 24, 48, and 72 h after surgery.
Treatment:
The compound, RAP-103, a CCR2/CCR5/CCR8 antagonist was tested for analgesic capacity. RAP-103 was supplied as a powder, and was reconstituted in sterile, pyrogen-free water. Solutions were prepared and kept frozen until use. On the day of the experiment, solutions were thawed and kept on ice until they were injected into rats. Rats were injected i.p., 25 min post-surgery. Control animals received water (vehicle). Morphine sulfate was dissolved in pyrogen-free saline and injected s.c. in the dorsal flank at 25 min post-surgery.
Co-Administration of RAP-103 with Morphine
In this experiment, RAP-103 at a single dose, 0.5 mg/kg, was combined with morphine (0.5 to 5.0 mg/kg) and the percent reversal of mechanical allodynia was compared to that of morphine alone at the different doses. The range of doses for morphine were previously established in our laboratory in this assay. FIG. 4 shows that when 5.0 mg/kg of morphine was compared to the same dose of morphine plus 0.5 mg/kg of RAP-103, statistically significantly greater analgesia was observed in animals receiving the combination treatment, than in rats receiving morphine alone.
Dose Response Curves of Morphine Alone Compared to Morphine Plus RAP-103
A comparison of morphine alone at different doses with morphine plus RAP-103 was tested in the incisional pain assay. Percent reversal of mechanical allodynia was calculated using data from t=60 min. % reversal=[(60 min threshold−predose threshold)/(baseline threshold−predose threshold)]×100. Data were analyzed by two-way ANOVA followed by Sidak's multiple comparison test, **p<0.01.
In FIG. 5 dose response curves are shown for morphine alone and for morphine plus RAP-103 (0.5 mg/kg) for ability to reverse mechanical allodynia, a measure of pain sensitivity. The ED50 values were calculated from the graphic dose-response curves. As shown, the ED50 for morphine was shifted to the left by about 2-fold by the addition of RAP-103. The ability of RAP-103 to potentiate opioid efficacy suggests further uses of RAP-103, and the related peptides of the invention, to be novel treatments for addictions in general, and opioid use disorders in particular.
  • Szabo, I., et al., Heterologous desensitization of opioid receptors by chemokines inhibits chemotaxis and enhances the perception of pain. Proc Natl Acad Sci USA, 2002. 99(16): p. 10276-81.
  • Chen, X., et al., Rapid heterologous desensitization of antinociceptive activity between mu or delta opioid receptors and chemokine receptors in rats. Drug Alcohol Depend, 2007. 88(1): p. 36-41.
  • Patil, P. R., et al., Opioid use in the management of diabetic peripheral neuropathy (DPN) in a large commercially insured population. Clin J Pain, 2015. 31(5): p. 414-24.

Claims (18)

What is claimed is:
1. A method of reducing the effective amount or duration of opioid in a patient using said opioids to manage pain comprising the steps of:
preparing a chemokine receptor antagonist pharmaceutical composition comprising an all-D peptide and a pharmaceutically acceptable carrier, said peptide comprises five contiguous amino acids and is at most 8 amino acid residues in length, having the general structure: A-B-C-D-E in which:
A is Ser, Thr, Asn, Glu, Ile,
B is Ser, Thr, Asp, Asn,
C is Thr, Ser, Asn, Arg, Trp,
D is Tyr, and
E is Thr, Ser, Arg, Gly,
all amino acids being the D stereoisomeric configuration and, administering said composition to the patient in a therapeutically effective dose,
wherein said composition acts to manage pain and reduce the effective amount or duration of opioid use in the patient.
2. The method as defined in claim 1 wherein said D peptide is TTNYT (SEQ ID NO: 1).
3. The method as defined in claim 1 wherein the D peptide has a sequence selected from the group consisting of:
(SEQ ID NO: 1) Thr Thr Asn Tyr Thr, (SEQ ID NO: 2) Ser Ser Thr Tyr Arg, (SEQ ID NO: 3) Ser Thr Asn Tyr Thr, (SEQ ID NO: 4) Thr Thr Ser Tyr Thr, (SEQ ID NO: 5) Asn Thr Ser Tyr Gly, (SEQ ID NO: 6) Glu Thr Trp Tyr Ser (SEQ ID NO: 7) Asn Thr Ser Tyr Arg (SEQ ID NO: 8) Ile Asn Asn Tyr Thr, (SEQ ID NO: 9) Ile Asp Asn Tyr Thr (SEQ ID NO: 10) Thr Asp Asn Tyr Thr (SEQ ID NO: 11) Thr Asp Ser Tyr Ser (SEQ ID NO: 12) Thr Asn Ser Tyr Arg (SEQ ID NO: 13) Asn Thr Arg Tyr Arg.
4. The method as defined in claim 1 wherein E is esterified, glycosylated, or amidated to enhance tissue distribution.
5. The method as defined in claim 1 wherein said composition is used as an oral pill having between 0.5 to 100 mgs of the peptide.
6. The method as defined in claim 1 wherein said composition is used as an oral pill having between 0.1 to 500 mgs of the peptide.
7. The method as defined in claim 1 wherein said chemokine receptor antagonist reduces the effective amount of opioid use by the patient.
8. The method as defined in claim 1 wherein said chemokine receptor antagonist is Dala1-peptide T-amide (DAPTA).
9. The method as defined in claim 1 wherein said chemokine receptor antagonist is Dala1-peptide T-amide (DAPTA) and is used to reduce the effective amount of opioid used by need for opioid used by the patient.
10. A method of pain treatment as defined in claim 1 wherein said chemokine receptor antagonist is administered as a pill or liquid.
11. A method of treating an opioid use disorder in a patient comprising:
administering to the patient a therapeutically effective dose of a pharmaceutical composition comprising an all-D peptide and a pharmaceutically acceptable carrier, wherein the all-D peptide comprises five contiguous amino acids and is at most 8 amino acid residues in length, having the general structure: A-B-C-D-E in which:
A is Ser, Thr, Asn, Glu, or Ile,
B is Ser, Thr, Asp, or Asn,
C is Thr, Ser, Asn, Arg, or Trp,
D is Tyr, and
E is Thr, Ser, Arg, or Gly,
wherein in the all-D peptide, all stereoisomeric amino acids are in the D stereoisomeric configuration, and wherein the pharmaceutical composition acts to treat the opioid use disorder in the patient.
12. The method of claim 11, wherein the all-D peptide is TTNYT (SEQ ID NO: 1), and wherein in the all-D peptide, all stereoisomeric amino acids are in the D stereoisomeric configuration.
13. The method of claim 11, wherein the all-D peptide has a sequence selected from the group consisting of:
(SEQ ID NO: 1) Thr Thr Asn Tyr Thr, (SEQ ID NO: 2) Ser Ser Thr Tyr Arg, (SEQ ID NO: 3) Ser Thr Asn Tyr Thr, (SEQ ID NO: 4) Thr Thr Ser Tyr Thr, (SEQ ID NO: 5) Asn Thr Ser Tyr Gly, (SEQ ID NO: 6) Glu Thr Trp Tyr Ser, (SEQ ID NO: 7) Asn Thr Ser Tyr Arg, (SEQ ID NO: 8) Ile Asn Asn Tyr Thr, (SEQ ID NO: 9) Ile Asp Asn Tyr Thr, (SEQ ID NO: 10) Thr Asp Asn Tyr Thr, (SEQ ID NO: 11) Thr Asp Ser Tyr Ser, (SEQ ID NO: 12) Thr Asn Ser Tyr Arg, and (SEQ ID NO: 13) Asn Thr Arg Tyr Arg, and wherein in the all-D peptide, all stereoisomeric amino acids are in   the D stereoisomeric configuration.
14. The method of claim 11, wherein E is esterified, glycosylated, or amidated.
15. The method of claim 11, wherein the pharmaceutical composition is in the form of an oral pill comprising from 0.5 mgs to 100 mgs of the all-D peptide and wherein the administering is oral administering.
16. The method of claim 11, wherein the pharmaceutical composition is in the form of an oral pill comprising from 0.1 mgs to 500 mgs of the all-D peptide and wherein the administering is oral administering.
17. The method of claim 11, wherein the pharmaceutical composition is in the form of a liquid.
18. A method of treating an opioid use disorder in a patient comprising:
administering to the patient a therapeutically effective dose of a pharmaceutical composition comprising Dala1-peptide T-amide (DAPTA), which is at most 8 amino acids in length, and a pharmaceutically acceptable carrier, wherein the administering of the pharmaceutical composition acts to manage pain and wherein the administering of the pharmaceutical composition acts to treat the opioid use disorder in the patient.
US17/701,974 2017-10-31 2022-03-23 Use of an all-D-pentapeptide chemokine antagonist to reduce opioid dose in a person with pain Active USRE50563E1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US17/701,974 USRE50563E1 (en) 2017-10-31 2022-03-23 Use of an all-D-pentapeptide chemokine antagonist to reduce opioid dose in a person with pain

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762579545P 2017-10-31 2017-10-31
US16/177,344 US10624945B2 (en) 2017-10-31 2018-10-31 Use of an all-D-pentapeptide chemokine antagonist to reduce opioid dose in a person with pain
US17/698,065 USRE50630E1 (en) 2017-10-31 2022-03-18 Use of an all-D-pentapeptide chemokine antagonist to reduce opioid dose in a person with pain
US17/701,974 USRE50563E1 (en) 2017-10-31 2022-03-23 Use of an all-D-pentapeptide chemokine antagonist to reduce opioid dose in a person with pain

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
US16/177,344 Reissue US10624945B2 (en) 2017-10-31 2018-10-31 Use of an all-D-pentapeptide chemokine antagonist to reduce opioid dose in a person with pain
US17/698,065 Continuation USRE50630E1 (en) 2017-10-31 2022-03-18 Use of an all-D-pentapeptide chemokine antagonist to reduce opioid dose in a person with pain

Publications (1)

Publication Number Publication Date
USRE50563E1 true USRE50563E1 (en) 2025-09-02

Family

ID=96876698

Family Applications (2)

Application Number Title Priority Date Filing Date
US17/698,065 Active USRE50630E1 (en) 2017-10-31 2022-03-18 Use of an all-D-pentapeptide chemokine antagonist to reduce opioid dose in a person with pain
US17/701,974 Active USRE50563E1 (en) 2017-10-31 2022-03-23 Use of an all-D-pentapeptide chemokine antagonist to reduce opioid dose in a person with pain

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US17/698,065 Active USRE50630E1 (en) 2017-10-31 2022-03-18 Use of an all-D-pentapeptide chemokine antagonist to reduce opioid dose in a person with pain

Country Status (1)

Country Link
US (2) USRE50630E1 (en)

Citations (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5063206A (en) 1988-12-16 1991-11-05 The United States Of Americas As Represented By The Department Of Health And Human Services Compositions having use as treatment of neuropsychiatric deficits
US5276016A (en) 1986-06-03 1994-01-04 The United States Of America As Represented By The Department Of Health And Human Services Small peptides which inhibit binding to T-4 receptors and act as immunogens
US5514670A (en) 1993-08-13 1996-05-07 Pharmos Corporation Submicron emulsions for delivery of peptides
US5529983A (en) 1986-06-03 1996-06-25 The United States Of America As Represented By The Department Of Health And Human Services Use of small peptides in the treatment of psoriasis
US5534495A (en) * 1993-05-25 1996-07-09 Advanced Peptides And Biotechnology Sciences Treatment of non-HIV neuropathic pain syndromes
US5567682A (en) 1988-12-16 1996-10-22 Advanced Peptides And Biotechnology Sciences Method of treating Alzheimer's disease
US5739109A (en) 1988-12-16 1998-04-14 Advanced Immunit Inc. Method of treating neuroinflammatory degenerative diseases
US5756449A (en) 1992-05-14 1998-05-26 Peptide Technology Limited Peptide T and related peptides in the treatment of inflammation, including inflammatory bowel disease
JPH11512732A (en) 1995-10-05 1999-11-02 ラボラトワール イノテラ ソシエテ アノニム Topical hormone therapy gel for vaginal dryness
US6011014A (en) * 1992-03-27 2000-01-04 Advanced Immunit, Inc. Peptide T and related peptides in the treatment of inflammation, including multiple sclerosis
US6242564B1 (en) 1986-06-03 2001-06-05 Candace B. Pert Treatment of tropical spastic paresis with peptide T
US20050013809A1 (en) 2002-12-02 2005-01-20 Owens Samuel M. Antibodies against drugs of abuse
US7390788B2 (en) 2005-06-23 2008-06-24 Pert Candace B Peptide pharmaceutical compositions
CN101309680A (en) 2005-07-12 2008-11-19 詹森药业有限公司 Use of 2-phenyl-1,2-ethanediol-(DI)carbamate in the treatment of epileptogenesis and epilepsy
US7700115B2 (en) 2005-06-23 2010-04-20 Rapid Pharmaceuticals Ag Therapeutic peptides and vaccines
WO2010084851A1 (en) 2009-01-23 2010-07-29 株式会社エム・エム・ティー Peptide capable of binding to immunoglobulin
US20110178013A1 (en) 2008-09-30 2011-07-21 Ipsen Pharma S.A.S. Novel octapeptide compounds derived from somatostatin and the therapeutic use thereof
US20110245180A1 (en) * 2010-02-09 2011-10-06 Rapid Pharmaceuticals, Ag Modified Peptide that reduces pain in peripheral neuropathy
WO2014047166A1 (en) 2012-09-19 2014-03-27 Transdermal Biotechnology, Inc. Techniques and systems for the treatment of neuropathic pain
US8772231B2 (en) 2006-06-23 2014-07-08 Aegis Therapeutics, Llc Stabilizing alkylglycoside compositions and methods thereof
US20140323393A1 (en) * 2013-04-26 2014-10-30 Michael Ruff Uses Of Peptides to Treat Brain Injury and Disease
US8916517B2 (en) 2009-11-02 2014-12-23 The Administrators Of The Tulane Educational Fund Analogs of pituitary adenylate cyclase-activating polypeptide (PACAP) and methods for their use
CN101084002B (en) 2004-09-02 2015-01-21 克格诺西有限公司 Improved analogues of APO E and methods of use thereof
US20170136095A1 (en) 2011-07-06 2017-05-18 The General Hospital Corporation Methods of Treatment Using A Pentapeptide Derived From The C-Terminus Of Glucagon-Like Peptide 1 (GLP-1)
WO2017167934A1 (en) 2016-03-30 2017-10-05 Genfit Non-invasive diagnostic of non-alcoholic steatohepatitis
WO2018087599A1 (en) 2016-11-10 2018-05-17 Galmed Research And Development Ltd. Treatment for fibrosis
WO2018129200A2 (en) 2017-01-05 2018-07-12 The Regents Of The University Of California Pac1 receptor agonists (maxcaps) and uses thereof
US20180344798A1 (en) * 2017-05-31 2018-12-06 Creative Bio-Peptides Inc. Topically active peptides for treating cosmetic and dermatological conditions
US20180360907A1 (en) * 2017-06-19 2018-12-20 Creative Bio-Peptides Inc. Anti-inflammatory peptides for treating non-alcoholic steatohepatitis (nash)
US20190022166A1 (en) 2017-07-18 2019-01-24 Creative Bio-Peptides Inc. Oral anti-inflammatory peptides to treat epilepsy, seizures and cns disorders
US20190125823A1 (en) 2017-10-31 2019-05-02 Creative Bio-Peptides Inc. Use Of An All-D-Pentapeptide Chemokine Antagonist To Reduce Opioid Dose In A Person With Pain
US20200246421A1 (en) 2017-10-12 2020-08-06 David Lovejoy Compositions, Methods and Uses for Treating Post-Traumatic Stress Disorder
US20200377579A1 (en) 2017-03-31 2020-12-03 Biogen International Neuroscience Gmbh Compositions and methods for treating synucleinopathies
US20210187057A1 (en) 2019-12-19 2021-06-24 Creative Bio-Peptides Inc. Methods and Compositions for Use of a Chemokine Receptor Antagonist Peptide to Treat Addiction, Substance Abuse Disorders or Symptoms Thereof
WO2022060424A1 (en) 2020-09-17 2022-03-24 Othair Prothena Limited β-AMYLOID VACCINE FOR THE TREATMENT OF ALZHEIMER'S DISEASE
WO2022192636A1 (en) 2021-03-12 2022-09-15 Eli Lilly And Company Anti-amyloid beta antibodies and uses thereof
WO2022246233A1 (en) 2021-05-20 2022-11-24 Creative Bio-Peptides, Inc. Compositions and methods for treating neuropathy

Patent Citations (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5863718A (en) 1986-06-03 1999-01-26 The United States Of America As Represented By The Department Of Health And Human Services Small peptides which inhibit to T-4 receptors and act as immunogens
US5529983A (en) 1986-06-03 1996-06-25 The United States Of America As Represented By The Department Of Health And Human Services Use of small peptides in the treatment of psoriasis
US5834429A (en) 1986-06-03 1998-11-10 The United States Of America As Represented By The Department Of Health And Human Services Small peptides which inhibit binding to T-4 receptors and act as immunogens
US6242564B1 (en) 1986-06-03 2001-06-05 Candace B. Pert Treatment of tropical spastic paresis with peptide T
US5276016A (en) 1986-06-03 1994-01-04 The United States Of America As Represented By The Department Of Health And Human Services Small peptides which inhibit binding to T-4 receptors and act as immunogens
US5739109A (en) 1988-12-16 1998-04-14 Advanced Immunit Inc. Method of treating neuroinflammatory degenerative diseases
US5567682A (en) 1988-12-16 1996-10-22 Advanced Peptides And Biotechnology Sciences Method of treating Alzheimer's disease
US5063206A (en) 1988-12-16 1991-11-05 The United States Of Americas As Represented By The Department Of Health And Human Services Compositions having use as treatment of neuropsychiatric deficits
US6011014A (en) * 1992-03-27 2000-01-04 Advanced Immunit, Inc. Peptide T and related peptides in the treatment of inflammation, including multiple sclerosis
US6265374B1 (en) 1992-03-27 2001-07-24 Advanced Immuni T, Inc. Peptide T and related peptides in the treatment of inflammation, including multiple sclerosis
US5756449A (en) 1992-05-14 1998-05-26 Peptide Technology Limited Peptide T and related peptides in the treatment of inflammation, including inflammatory bowel disease
US5534495A (en) * 1993-05-25 1996-07-09 Advanced Peptides And Biotechnology Sciences Treatment of non-HIV neuropathic pain syndromes
US5514670A (en) 1993-08-13 1996-05-07 Pharmos Corporation Submicron emulsions for delivery of peptides
JPH11512732A (en) 1995-10-05 1999-11-02 ラボラトワール イノテラ ソシエテ アノニム Topical hormone therapy gel for vaginal dryness
US20050013809A1 (en) 2002-12-02 2005-01-20 Owens Samuel M. Antibodies against drugs of abuse
CN101084002B (en) 2004-09-02 2015-01-21 克格诺西有限公司 Improved analogues of APO E and methods of use thereof
US7700115B2 (en) 2005-06-23 2010-04-20 Rapid Pharmaceuticals Ag Therapeutic peptides and vaccines
US7390788B2 (en) 2005-06-23 2008-06-24 Pert Candace B Peptide pharmaceutical compositions
US10071153B2 (en) 2005-06-23 2018-09-11 Michael Ruff Therapeutic peptides and vaccines
CN101309680A (en) 2005-07-12 2008-11-19 詹森药业有限公司 Use of 2-phenyl-1,2-ethanediol-(DI)carbamate in the treatment of epileptogenesis and epilepsy
US8772231B2 (en) 2006-06-23 2014-07-08 Aegis Therapeutics, Llc Stabilizing alkylglycoside compositions and methods thereof
US20110178013A1 (en) 2008-09-30 2011-07-21 Ipsen Pharma S.A.S. Novel octapeptide compounds derived from somatostatin and the therapeutic use thereof
WO2010084851A1 (en) 2009-01-23 2010-07-29 株式会社エム・エム・ティー Peptide capable of binding to immunoglobulin
US8916517B2 (en) 2009-11-02 2014-12-23 The Administrators Of The Tulane Educational Fund Analogs of pituitary adenylate cyclase-activating polypeptide (PACAP) and methods for their use
US20110245180A1 (en) * 2010-02-09 2011-10-06 Rapid Pharmaceuticals, Ag Modified Peptide that reduces pain in peripheral neuropathy
US10130674B2 (en) * 2010-02-09 2018-11-20 Creative Bio-Peptides Modified peptide that reduces pain in peripheral neuropathy
US20170136095A1 (en) 2011-07-06 2017-05-18 The General Hospital Corporation Methods of Treatment Using A Pentapeptide Derived From The C-Terminus Of Glucagon-Like Peptide 1 (GLP-1)
WO2014047166A1 (en) 2012-09-19 2014-03-27 Transdermal Biotechnology, Inc. Techniques and systems for the treatment of neuropathic pain
US20170080019A1 (en) 2012-09-19 2017-03-23 Transdermal Biotechnology, Inc. Techniques and systems for treatment of neuropathic pain and other indications
US20140322252A1 (en) 2013-04-26 2014-10-30 Michael Ruff Peptides for Treating Alzheimers's Disease and Related Conditions
US10501494B2 (en) * 2013-04-26 2019-12-10 Creative Bio-Peptides Uses of peptides to treat brain injury and disease
US20140322251A1 (en) * 2013-04-26 2014-10-30 Michael Ruff Peptides for Progressive Treating Multi-Focal Leukoencephalopathy and Related Conditions
US20140323393A1 (en) * 2013-04-26 2014-10-30 Michael Ruff Uses Of Peptides to Treat Brain Injury and Disease
US20140322250A1 (en) * 2013-04-26 2014-10-30 Michael Ruff Peptides for the Treatment of Multiple Sclerosis and Related Diseases
WO2017167934A1 (en) 2016-03-30 2017-10-05 Genfit Non-invasive diagnostic of non-alcoholic steatohepatitis
WO2018087599A1 (en) 2016-11-10 2018-05-17 Galmed Research And Development Ltd. Treatment for fibrosis
WO2018129200A2 (en) 2017-01-05 2018-07-12 The Regents Of The University Of California Pac1 receptor agonists (maxcaps) and uses thereof
US20200377579A1 (en) 2017-03-31 2020-12-03 Biogen International Neuroscience Gmbh Compositions and methods for treating synucleinopathies
US20180344798A1 (en) * 2017-05-31 2018-12-06 Creative Bio-Peptides Inc. Topically active peptides for treating cosmetic and dermatological conditions
US20180360907A1 (en) * 2017-06-19 2018-12-20 Creative Bio-Peptides Inc. Anti-inflammatory peptides for treating non-alcoholic steatohepatitis (nash)
US20190022166A1 (en) 2017-07-18 2019-01-24 Creative Bio-Peptides Inc. Oral anti-inflammatory peptides to treat epilepsy, seizures and cns disorders
WO2020018315A2 (en) 2017-07-18 2020-01-23 Creative Bio-Peptides Inc. Oral anti-inflammatory peptides to treat epilepsy, seizures and cns disorders
US20200246421A1 (en) 2017-10-12 2020-08-06 David Lovejoy Compositions, Methods and Uses for Treating Post-Traumatic Stress Disorder
US20190125823A1 (en) 2017-10-31 2019-05-02 Creative Bio-Peptides Inc. Use Of An All-D-Pentapeptide Chemokine Antagonist To Reduce Opioid Dose In A Person With Pain
US20210187057A1 (en) 2019-12-19 2021-06-24 Creative Bio-Peptides Inc. Methods and Compositions for Use of a Chemokine Receptor Antagonist Peptide to Treat Addiction, Substance Abuse Disorders or Symptoms Thereof
US11510961B2 (en) * 2019-12-19 2022-11-29 Creative Bio-Peptides, Inc. Methods and compositions for use of a chemokine receptor antagonist peptide to treat addiction, substance abuse disorders or symptoms thereof
WO2022060424A1 (en) 2020-09-17 2022-03-24 Othair Prothena Limited β-AMYLOID VACCINE FOR THE TREATMENT OF ALZHEIMER'S DISEASE
WO2022192636A1 (en) 2021-03-12 2022-09-15 Eli Lilly And Company Anti-amyloid beta antibodies and uses thereof
WO2022246233A1 (en) 2021-05-20 2022-11-24 Creative Bio-Peptides, Inc. Compositions and methods for treating neuropathy

Non-Patent Citations (135)

* Cited by examiner, † Cited by third party
Title
Abboud, et al., Inflammation Following Traumatic Brain Injury in Humans: Insights from Data-Driven and Mechanistic Models into Survival and Death. Front Pharmacol, 2016, vol. 7, 342.
Altman et al., Failure of vaccine test is setback in AIDS fight, New York Times, Sep. 22, 2007, 2 pages.
Amphetamines from www.DEA.gov, p. 1-4, Access Oct. 26, 2021 (2021).
Arisi, et al., Increased CCL2, CCL3, CCL5, and IL-1β cytokine concentration in piriform cortex, hippocampus, and neocortex after pilocarpine-induced seizures. J Neuroinflammation, 2015, vol. 12, 129, p. 1-7.
Bamburg, et al., Actin dynamics and cofilin-actin rods in Alzheimer disease, Cytoskeleton, 2016, vol. 73, No. 9, p. 477-497.
Bamburg, et al., ADF/cofilin-actin rods in neurodegenerative diseases, Curr Alzheimer Res., 2010, vol. 7, No. 3, p. 241-250.
Barbey-Morel C, McDonnell K, Ruff, MR, Pert C. A Peptide T Bolus Normalizes Growth Hormone Secretion Pattern in Two Children with AIDS. Peptides; 2002, vol. 6538, p. 1-3.
Barrett, et al., NOX2 deficiency alters macrophage phenotype through an IL-10/STAT3 dependent mechanism: Implications for traumatic brain injury. J Neuroinflammation, 2017, vol. 14(65), p. 1-17.
Bongiovanni et al., Mutli-chemokine receptor antagonist RAP-103 inhibits opioid-derived respiratory depression, reduces opioid reinforcement and physical dependence, and noramlizes opioid-induced dysregulation of mseolimbic chemokine receptors in rates, Drug Alcohol Depend., 2022, vol. 238, p. 1-31.
Bongiovanni, et al., Reduction of opioid reinforcement and physical dependence, inhibition of opioid-induced respiratory depression and normalization of opioid-induced dysregulation of mesolimbic chemokine receptors, Alcohol & Drug Abuse, 2022, vol. 238, p. 1-31.
Brenneman et al., Peptide T sequences prevent neuronal cell death produced by the envelope protein (gp120) of the human immunodeficiency virus. Drug Devel Res, 1988, vol. 15, p. 361-369.
Brenneman, D.E., Westbrook, G.L., Fitzgerald, S.P., Ennist, D.L., Elkins, K.L., Ruff, M.R. and Pert, C.B. Neuronal cell killing by the envelope protein of HIV and its prevention by vasoactive intestinal peptide. Nature, 1988, vol. 335, p. 639-642.
Brenneman, DE., Hauser, JM, Spong CY., Phillips, TM., Pert, CB., and Ruff, MR. VIP and D-Ala1-Peptide T-amide release chemokines which prevent HIV-1 gp120 induced neuronal death. Brain Res., 1999, vol. 838, p. 27-36.
Bridge, T.P., Heseltine, P.N.R., Parker, E.S., Eaton, E., Ingraham, L.J., Gill, M., Ruff, M.R., Pert, C.B., and Goodwin, F.K. Improvements in AIDS patients on peptide T. The Lancet, 1989, p. 226-227.
Cai et al., Two different molecular mechanisms underlying progesterone neuroprotection against ischemic brain Damage. Neuropharmacology, 2008, vol. 55, p. 127-38.
Cataldo et al., The bivalent ligand MCC22 potently attenuates hyperalgesia in a mouse model of cisplatin-evoked neuropathic pain without tolerance or reward, Neuropharmacology, v158, Apr. 7, 2019, p. 1-28.
CDC Overdose Prevention. Understanding the opioid overdose epidemic. Nov. 1, 2024, downloaded Feb. 19, 2025; https://www.cdc.gov/overdose-prevention/about/understanding-the-opioid-overdose-epidemic.html.
Cerri, et al., The Chemokine CCL2 Mediates the Seizure-enhancing Effects of Systemic Inflammation. J Neurosci, 2016, vol. 36, p. 3777-3788.
Chapa-Oliver et al., Capsaicin: From Plants to a Cancer-Suppressing Agent, Molecules, Jul. 27, 2016, v21(8), p. 1-14.
Chen C, Zhang XR, Ju ZY, He WF., Advances in the research of cytokine storm mechanism induced by Corona Virus Disease 2019 and the corresponding immunotherapies, Chinese Journal of Burns. 2020; vol. 36(06), p. 471-475, E005, Epub Mar. 3, 2020.
Chen et al., Rapid heterologous desensitization of antinociceptive activity between mu or delta opioid receptors and chemokine receptors in rats. Drug Alcohol Depend, 2007, vol. 88, No. 1, p. 36-41.
Chen Y, Guo Y, Pan Y, Zhao ZJ. Structure analysis of the receptor binding of 2019-nCo V. Biochem Biophys Res Commun. 2020. Epub Feb. 23, 2020.
Cichon et al., Cofilin Aggregation Blocks Intracellular Trafficking and Induces Synaptic Loss in Hippocampal Neurons, Journal of Biological Chemistry, vol. 287, No. 6, p. 3919-2929, 2012.
Crews et al. Induction of innate immune genes in brain create the neurobiology of addiction. Brain, Behavior, and Immunity, 2011, vol. 25, Suppl 1, S4-S12. Epub Mar. 16, 2011.
Dhote et al., Prolonged inflammatory gene response following soman-induced seizures in mice. Toxicology, 2007, vol. 238, p. 166-176.
Di Prisco, et al., Functional adaptation of presynaptic chemokine receptors in EAE mouse central nervous system. Synapse, 2014, vol. 68, p. 529-535.
Di Prisco, et al., Rantes-mediated control of excitatory amino acid release in mouse spinal cord. J Neurochem, 2012, vol. 121, p. 428-437.
Dillman, et al., Gene expression profiling of rat hippocampus following exposure to the acetylcholinesterase inhibitor soman. Chem Res Toxicol 2009, vol. 22, p. 633-638.
Donaghy et al., The clinical characteristics of dementia with Lewy bodies and a consideration of prodromal diagnosis, Alzheimer's Research & Therapy, 2014, vol. 6, No. 46, p. 1-12.
Ensign, et al., Nanoparticle-based drug delivery to the vagina: A review. J Control Release, 2014, p. 500-514.
Fan, Y et al., MKEY, a Peptide Inhibitor of CXCL4-CCL5 Heterodimer Formation, Protects Against Stroke in Mice. Journal of the American Heart Association. Sep. 15, 2016, vol. 5, No. 9; pp. 1-8.
Feng, Z et al., Inspiration from the mirror: D-amino acid containing peptides in biomedical approaches. Biomolecular Concepts. Jun. 1, 2016, vol. 7, No. 3; pp. 179-187.
Flannery, et al., Persistent neuroinflammation and cognitive impairment in a rat model of acute diisopropylfluorophosphate intoxication. J Neuroinflammation 2016, vol. 13, No. 267, p. 1-16.
Funke, SA et al., Peptides for Therapy and Diagnosis of Alzheimer's Disease. Current Pharmaceutical Design. 2012, vol. 18, No. 6; pp. 755-767.
Galvin JE et al., Clinical phenotype of Parkinson disease dementia, Neurology, 2006, vol. 67, No. 9, p. 1605-1611.
Gibson et al., Feasibility of progesterone treatment for ischaemic stroke. J. Cerebral Blood Flow & Metabolism, 2016, vol. 36(3), p. 487-91.
Goodwin et al., "Peptides as therapeutics with enhanced bioactivity" Current Medicinal Chemistry 2012, vol. 19, p. 4451-4461.
Hayball, P. J. 1996. Chirality and nonsteroidal anti-inflammatory drugs. Drugs vol. 52 Suppl 5: p. 47-58.
He et al., Increased MCP-1 and microglia in various regions of the human alcoholic brain. Experimental Neurology, 2008, vol. 210(2), p. 349-58. Epub Jan. 15, 2008.
Heijo et al., Interactions Between Peptide and Preservatives: Effects on Peptide Self-Interactions and Antimicrobial Efficiency in Aqueous Multi-Dose Formulations, Pharm Res, 2015, vol. 32, p. 3201-3212.
Heseltine, et al., Randomized double-blind placebo-controlled trial of peptide T for HIV-associated cognitive Impairment. Arch Neurol, 1998, vol. 55, p. 41-51.
Hill et al., HIV envelope protein-induced neuronal damage and retardation of behavioral development in rat neonates. Brain Res, 1993, vol. 603(2), p. 222-33.
Huang et al., Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020, vol. 395, No. 10223, p. 497-506. Epub Jan. 28, 2020.
International Search Report and Written Opinion for PCT/US2019/037627, mailed Sep. 30, 2019.
International Search Report and Written Opinion for PCT/US2022/030305, mailed Sep. 13, 2022.
International Search Report and Written Opinion for PCT/US2022/032835, mailed Oct. 9, 2022.
International Search Report and Written Opinion for PCT/US2024/014413, mailed Aug. 23, 2024.
International Search Report and Written Opinion for PCT/US2024/030461, mailed Oct. 11, 2024.
International Search Report for PCT/US19/40977 mailed Jan. 13, 2020.
Jellinger et al., Are dimentia with Lewy bodies and Parkinson's disease dementia he same disease?, BMC Medicine, 2018, vol. 16, No. 34, p. 1-16.
Jiang et al., Chemokines in chronic pain: cellular and molecular mechanisms and therapeutic potential, Pharmacology & Therapeutics, May 22, 2020, v212, p. 1-25.
Joy et al., CCR5 Is a Therapeutic Target for Recovery after Stroke and Traumatic Brain Injury. Cell, 2019, vol. 176(5), p. 1143-57 e13. Epub Feb. 23, 2019.
Kang et al., Cofilin, a Master Node Regulating Cytoskeletal Pathogenesis in Alzheimer's Disease, Journal of Alzheimer's Disease, 2019, vol. 72, S131-S144.
Kim et al., Chemokines and cocaine: CXCR4 receptor antagonist AMD3100 attenuates cocaine place preference and locomotor stimulation in rats. Brain, Behavior, and Immunity, 2017, vol. 62, p. 30-4. Epub Aug. 31, 2016.
Lee et al., Decreased pain responses of C-C chemokine receptor 5 knockout mice to chemical or inflammatory stimuli. Neuropharmacology, 2013, vol. 67, p. 57-65.
Lee et al., Neuropharmacology, 67:57-65, 2013. *
Li et al., Advances in the use of opioids in treating neuropathic cancer pain, Ann Palliat Med, 2012, vol. 1, No. 1, p. 53-57.
Li, et al., Effects of CC-chemokine receptor 5 on ROCK2 and P-MLC2 expression after focal cerebral ischaemia-reperfusion injury in rats. Brain Inj, 2016, vol. 30, p. 468-473.
Libow LS et al., Parkinson's disease dementia: a diminshed role for the Lewy body, Parkinsonism Relat Disor., 2009, vol. 15, No. 8, p. 572-575.
Louboutin, et al., Role of CCR5 and its ligands in the control of vascular inflammation and leukocyte recruitment required for acute excitotoxic seizure induction and neural damage. FASEB J, 2011, vol. 25, p. 737-753.
Lusso et al., Cryptic Nature of a Conserved, CD4-Inducible V3 Loop Neutralization Epitope in the Native Envelope Glycoprotein Oligomer of CCR5-Restricted, but Not CXCR4-Using, Primary Human Immunodeficiency Virus Type 1 Strains. J Virol. 2005, vol. 79(11), p. 6957-68.
Mahalakshmi et al., The Use of D-Amino Acids in Peptide Design, New Frontier in Amino Acid and Protein Research, 2006, Chapter 5.9, p. 415-430.
Majchrzak et al., The newest cathinone derivatives as designer drugs: an analytical and toxicological review, Forensic Toxicol, 2018, vol. 36, p. 33-50.
Mao, et al., Exogenous administration of PACAP alleviates traumatic brain injury in rats through a mechanism involving the TLR4/MyD88/NF-κB pathway. J Neurotrauma, 2012, vol. 29, p. 1941-1959.
Marastoni et al. Synthesis, metabolic stability and chemotactic activity of peptide T and its analogues. J Peptide Protein Res. 1990. vol. 35, p. 81-88.
Mayo Clinic (https ://www .mayoclinic.org/diseases-conditions/traumatic-brain-injury/diagnosis-treatment/drc-20378561, 2019.
Mehta et al., Across Speciality Collaboration UK. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020. Epub Mar. 13, 2020.
Melgarejo, et al., Monocyte chemoattractant protein-I: a key mediator in inflammatory processes. The International Journal of Biochemistry & Cell Biology. 2009; vol. 41(5): p. 998-1001. Epub Sep. 2, 2008.
Merck Manual (<https://www.merckmanuals.com/professional/neurologic-disorders/peripheral-nervous-system-and-motor-unit-disorders/amyotrophic-lateral-sclerosis-als-and-other-motor-neuron-diseases-mnds> accessed on Sep. 17, 2021).
Moore et al. In vivo depression of lymphocyte traffic in sheep by VIP and HIV (AIDS)-related peptides. Immunopharmacology, 1988, vol. 16, p. 181-89.
Morganti, et al., Age exacerbates the CCR2/5-mediated neuroinflammatory response to traumatic brain injury. J Neuroinflammation 2016, vol. 13, p. 1-12.
Mulroney, S.E., K.J. McDonnell, C.B. Pert, M.R. Ruff, Z. Resch, W.K. Samson, and M.D. Lumpkin. HIV gp120 Inhibits the somatotropic axis: a possible GH-releasing hormone receptor mechanism for the pathogenesis of AIDS wasting. Proc Natl Acad Sci USA, 1998, vol. 95, p. 1927-1932.
Nayak et al., Chemokine CCR5 and cocaine interactions in the brain: Cocaine enhances mesolimbic CCR5 mRNA levels and produces place preference and locomotor activation that are reduced by a CCR5 antagonist. Brain, Behavior, and Immunity, 2020, vol. 83, 288-92. Epub Sep. 27, 2019.
NIH (<https://www.ninds.nih.gov/Disorders/All-Disorders/Encephalopathy-Information-Page> accessed Aug. 3, 2018).
Noda, M, Daichi T, Ruff, MR and C. Pert. Neuropathic pain inhibitor, RAP-103, is a potent inhibitor of microglial CCL1/CCR8. Neurochem Int., 2017, vol. 119, p. 1-6.
Owen et al., A theta-defensin composed exclusively of D-amino acids is active against H I V-1. J. Peptide Res, 2004, vol. 53, p. 469-76.
Padi et al., Attenuation of rodent neuropathic pain by an orally active peptide, RAP-103, which potently blocks CCR2- and CCR5-mediated monocyte chemotaxis and inflammation. Pain, 2012, vol. 153(1), p. 95-106. PubMed PMID: 22033364.
Paoletti, et al., Amygdalin analogues inhibit IFN-gamma signalling and reduce the inflammatory response in human epidermal keratinocytes. Inflammation, 2013, vol. 36, p. 1316-1326.
Patil et al., Opioid use in the management of diabetic peripheral neuropathy (DPN) in a large commercially insured population. Clin J Pain, 2015, vol. 31, No. 5, p. 414-24.
Peiris JS, Guan Y, Yuen KY. Severe acute respiratory syndrome. Nat Med. 2004; vol. 10(12 Suppl), S88-97. Epub Dec. 4, 2004.
Pert et al., Octapeptides deduced from the neuropeptide receptor-like pattern of antigen T 4 in brain potently inhibit human immunodeficiency virus receptor binding and T-cell infectivity. Proc Natl Acad Sci USA, 1986, vol. 83, p. 9254-9258.
Pevida et al., The chemokine CCL5 induces CCR1-mediated hyperalgesia in mice inoculated with NCTC 2472 tumoral cells, Neuroscience, Dec. 4, 2013, v259, p. 113-125.
Polianova et al., Chemokine receptor-5 {CCR5) is a receptor for the HIV entry inhibitor peptide T (DAPTA), Antiviral Res. 200, vol. 67, p. 83-92.
Polianova, MT, Ruscetti FW, Pert CB, Leoung, G, Strang, S, Ruff, MR. Antiviral and immunological benefits in HIV patients receiving intranasal peptide T (DAPTA). Peptides, 2003, vol. 24, p. 1093-1098.
Polito, et al., Epithelia cells as regulators of airway inflammation. The Journal of Allergy and Clinical Immunology. 1998, vol. 102(5), p. 714-8. Epub Dec. 29, 1998.
Pollicita M, Ruff MR, Pert CB, Polianova MT, Schols D, Ranazzi A, Perno CF, Aquaro S. Profound anti-HIV-1 activity of DAPTA in monocytes/macrophages and inhibition of CCR5-mediated apoptosis in neuronal cells. Antivir Chem Chemother, 2007, vol. 18, p. 285-95.
Rachaudhuri S. P., E. M. Farber, and S. K. Raychaudhuri. 1999. Immunomodulatory effects of peptide T on Th 1/Th 2 cytokines. Int J Immunopharmacol, 1999, vol. 21, p. 609-15.
Ravizza, et al., Innate and adaptive immunity during epileptogenesis and spontaneous seizures: evidence from experimental models and human temporal lobe epilepsy. Neurobiol Dis, 2008, vol. 29, p. 142-160.
Rosi et al. Chemokine receptor 5 antagonist d-ALA-peptide T-amide reduces microglia and astrocyte activation within the hippocampus in a neuroinflammatory rat model of alzheimer's disease. Neuroscience, 2005, vol. 134, p. 671-676.
Ruan et al., Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Medicine. 2020. Epub Mar. 4, 2020.
Ruff et al., CD4 receptor binding peptides that block HIV infectivity cause human monocyte chemotaxis. Relationship o vasoactive intestinal polypeptide. FEBS Lett, 1987, vol. 211, p. 17-22.
Ruff et al., Peptide T[4-8] is Core HIV Envelope Sequence Required for CD4 Receptor Attachment, Lancet. 1987. vol. 330(8561), p. 751.
Ruff et al., Update on D-ala-peptide T-amide (DAPTA): a viral entry inhibitor that blocks CCR5 chemokine receptors. Curr HIV Res, 2003, vol. 1, p. 51-67.
Ruff, et al., Potentiation of Morphine Antinociception and Inhibition of Diabetic Neuropathic Pain by the Multi-Chemokine Receptor Antagonist Peptide RAP-103, Life Science, 2022, vol. 306, p. 1-9.
Ruff, M.R., Smith, C., Kingan, T., Jaffe, H., Heseltine, P., Gill, M.A., Mayer, K., Pert, C.B., and Bridge, T.P. Pharmacokinetics of peptide T in patients with acquired immunodeficiency syndrome (AIDS). Prog Neuro Psychopharm., 1991, vol. 15, p. 791-801.
Ruff, MR., Loyda M. Melendez-Guerrero., Quan-en Yang., Wen-Zhe Ho., Judy Mikovits, Candace B. Pert, and Francis Ruscetti. 2001. Peptide T inhibits HIV-1 infection mediated by the chemokine receptor-5 (CCR5). Antiviral Res., 2001, vol. 52, p. 63-75.
Saez-Torres et al., Peptide T does not ameliorate experimental autoimmune encephalomyelitis (EAE) in Lewis rats, Clin. Exp. Lmmunol, 2000, vol. 121, p. 151-56.
Saika et al., CC-chemokine ligand 4/macrophage inflammatory protein-1beta participates in the induction of neuropathic pain after peripheral nerve injury. Eur J Pain, 2012, vol. 16, p. 1271-1280.
Saika et al., Chemokine CXCL1 is responsible for cocaine-induced reward in mice. Neuropsychopharmacology Reports. 2018, vol. 38(3), p. 145-8. Epub Sep. 4, 2018.
Schulz-Schaeffer, The synaptic pathology of α-synuclein aggregation in dementia with Lewy bodies, Parkinson's disease and Parkinson's disease dementia, Acta Neuropathol, 2010, vol. 120, p. 131-143.
Servick, Unexpected drug emerges for stroke recovery. Science. Feb. 22, 2019. vol. 363(6429), p. 805.
Shaw et al., Peptide Regulation of Cofilin Activity in the CNAS: A Novel Therapeutic Approach for Treatment of Multiple Neurological Disorders, Pharmacology & Therapeutics, 2017, vol. 175, p. 17-27.
Shen et al., . Postnatal activation of TLR4 in astrocytes promotes excitatory synaptogenesis in hippocampal neurons. J Cell Biol, 2016, vol. 215, p. 719-734.
Shi et al., COVID-19 infection: the perspectives on immune responses. Cell Death Differ. 2020. Epub Mar. 25, 2020.
Silva et al., Cofilin pathology is a new player on α-synuclein-induced spine impairment in modles of hippocampal synucleinopathy, bioRxiv, Feb. 2, 2021, p. 1-24.
Smith et al., Tritiated D-ala-peptide T binding: A pharmacologic basis for the design of drugs which inhibit HIV receptor binding. Drug Development Res, 1988, vol. 15, p. 371-379.
Song et al., "Effects of an Inhibitor of Monocyte Recruitment on Recovery from Traumatic Brain Injury in Mice Treated with Granulocyte Colony-Stimulating Factor," Int. J. Mol. Sci. Jul. 2, 2017; vol. 18(7), p. 1-16.
Song et al., Pharmacological Modulation of Functional Phenotypes of Microglia in Neurodegenerative Diseases. Front Aging Neurosci, 2017, vol. 9, p. 1-10.
Spisani et al. Chemotactic response of human monocytes to pentapeptide analog derived from immunodeficiency virus protein gp 120. Inflammation, 1990, vol. 14(1), p. 55-60.
Stern et al. Drug Delivery: Oral Delivery of Peptides by Petelligence Technology. Drug Development and Delivery. Accessed online at https://drug-dev.com/oral-delivery-of-peptides-by-peptelligence-technology/ on Aug. 5, 2019, 10 pages. (Year: 2013). *
Stewart et al., All-D-bradykinin and the problem of peptide antimetabolites. Nature, vol. 206, p. 619-620.
Szabo et al., Heterologous desensitization of opioid receptors by chemokines inhibits chemotaxis and enhances the perception of pain. Proc Natl Acad Sci USA, 2002, vol. 99, No. 16, p. 10276-81.
The Concussion Legacy Foundation (https://concussionfoundation .org/CTE-resources/what-is-CTE, 2019).
Thermo, N-Terminal Acetylation and C-Terminal Amidation of Peptides. Technical Information, 2004, 2 pages.
Thermo. Technical Information. "N-Terminal Acetylation and C-Terminal Amidation of Peptides". 2004, 2 pages. (Year: 2004). *
Trocello et al., Implication of CCR2 chemokine receptor in cocaine-induced sensitization. J Mol Neurosci. 2011, vol. 44(3), p. 147-51. Epub Mar. 23, 2011.
U.S. Appl. No. 17/698,065, filed Mar. 18, 2022, Ruff, Michael R.
U.S. Appl. No. 17/816,448, filed Aug. 1, 2022, Ruff, Michael R.
U.S. Appl. No. 17/869,925, filed Jul. 21, 2022, Ruff, Michael R.
Uludag et al., IL-1β, IL-6 and IL1Ra levels in temporal lobe epilepsy. Seizure, vol. 26, p. 22-25.
US Food and Drug Administration. FDA's Efforts to Address the Misuse and Abuse of Opioids. Feb. 6, 2013, downloaded Feb. 19, 2025; https://www.fda.gov/drugs/information-drug-class/fdas-efforts-address-misuse-and-abuse-opioids.
Valekova et al., Revelation of the IFNα, IL-10, IL-8 and IL-1β as promising biomarkers reflecting immuno-pathological mechanisms in porcine Huntington's disease model. J Neuroimmunol, 2016 vol. 293, p. 71-81.
Vezzani et al., Brain inflammation as a biomarker in epilepsy. Biomark Med, 2011, vol. 5, p. 607-614.
Vezzani et al., The role of inflammation in epilepsy. Nat Rev Neurol, 2011, vol. 7, p. 31-40.
Victoria, et al. Knockdown of C-C chemokine receptor 5 (CCR5) is protective against cerebral ischemia and reperfusion injury. Curr Neurovasc Res, 2017, vol. 14, No. 2, pp. 125-131.
Villemagne et al., Peptide T and glucose metabolism in AIDS dementia complex. J Nucl Med, 1996, vol. 37, 1177-1180.
Vitaliti et al., Targeting inflammation as a therapeutic strategy for drug-resistant epilepsies: an update of new immune-modulating approaches. Hum Vaccin Immunother, 2014, vol. 10, 868-875.
Wakabayashi et al., The Lewy body in Parkinson's disease: Molecules implicated in the formation and degradation of α-synuclein aggregates, Neuropathology, 2007, vol. 27, p. 494-506.
Walsh et al., Amyloid-β and Proinflammatory Cytokines Utilize a Prion Protein-Dependent Pathway to Activate NADPH Oxidase and Induce Cofilin-Actin Rods in Hippocampal Neurons, PLOS One, 2014, vol. 9, Issue 4, e95995, p. 1-12.
Xu et al., Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020. Epub Feb. 23, 2020.
Yan et al., Cofilin 1 promotes the aggregation and cell-to-cell transmission of asynuclein in Parkinson's disease, Biochemical & Biophysical Research Commun, 2020, vol. 529, p. 1053-1060.
Yoshikawa et al., Severe acute respiratory syndrome (SARS) coronavirus-induced lung epithelial cytokines exacerbate SARS pathogenesis by modulating intrinsic functions of monocyte-derived macrophages and dendritic cells. J Virol. 8 2009, vol. 83(7), p. 3039-48. Epub Nov. 14, 2008.
Yousefzadeh-Chabok et al., "The Relationship Between Serum Levels of Interleukins 6, 8, 10 and Clinical Outcome in Patients with Severe Traumatic Brain Injury." Arch Trauma Res, 2015, vol. 4(1), p. e18357.
Zhao, Q., Dual targeting of CCR2 and CCR5: therapeutic potential for immunologic and cardiovascular diseases. J Leukoc Biol, 2010, vol. 88, Issue 1, p. 41-55.
Zhou et al., CCR5 is a suppressor for cortical plasticity and hippocampal learning and memory. Elife. 2016;5. Epub Dec. 21, 2016.

Also Published As

Publication number Publication date
USRE50630E1 (en) 2025-10-14

Similar Documents

Publication Publication Date Title
TWI451868B (en) Improvements in and relating to medicinal compositions
US10624945B2 (en) Use of an all-D-pentapeptide chemokine antagonist to reduce opioid dose in a person with pain
EP2125019B1 (en) Improved medicinal compositions comprising buprenorphine and naltrexone
JP2004512260A (en) Local anesthesia / opioid preparation and method of use
SI21025A (en) Analgesic compositions containing buprenorphine
US20100168147A1 (en) Medicinal Compositions Comprising Buprenorphine And Naloxone
FI3356386T3 (en) Method of treating melanocortin-4 receptor pathway-associated disorders
EP2114452B1 (en) Improved medicinal compositions comprising buprenorphine and nalmefene
USRE50563E1 (en) Use of an all-D-pentapeptide chemokine antagonist to reduce opioid dose in a person with pain
RU2476209C1 (en) Implanted drug preparation of naltrexone for treating alcohol- or opioid-dependent patients
JP2023109829A (en) Treatment method and its dosage form
RU2475272C1 (en) Implantable medication disulfiram-based for treatment of alcohol or opiate-dependent patient
EP3765056B1 (en) Compositions, methods and uses of a teneurin c-terminal associated peptide-1 (tcap-1) for treating opioid addiction
RU2495679C1 (en) Disulphiram implant for treating alcohol or opiate addictive patients
HK40046105B (en) Compositions, methods and uses of a teneurin c-terminal associated peptide-1 (tcap-1) for treating opioid addiction
HK40046105A (en) Compositions, methods and uses of a teneurin c-terminal associated peptide-1 (tcap-1) for treating opioid addiction
WO1995017189A1 (en) NEW USE OF δ-OPIOID RECEPTOR ANTAGONISTS
HK1139871B (en) Improvements in and relating to medicinal compositions
HK1139867A (en) Improved medicinal compositions comprising buprenorphine and naltrexone
AU2014201777A1 (en) Improvements in and relating to medicinal compositions
AU2014201779A1 (en) Improved medicinal compositions comprising buprenorphine and naloxone
HK1139868B (en) Improved medicinal compositions comprising buprenorphine and nalmefene
DE102007040932A1 (en) Liquid granulocyte colony-stimulating factor formulation, e.g. for treating cancer, neutropenia, HIV infections or neurological disorders, comprises a sugar alcohol, surfactant and acetate buffer

Legal Events

Date Code Title Description
FEPP Fee payment procedure

Free format text: ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: BIG.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

FEPP Fee payment procedure

Free format text: ENTITY STATUS SET TO SMALL (ORIGINAL EVENT CODE: SMAL); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

AS Assignment

Owner name: CREATIVE BIO-PEPTIDES, INC., MARYLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:RUFF, MICHAEL R.;REEL/FRAME:066399/0235

Effective date: 20181031

Owner name: CREATIVE BIO-PEPTIDES, INC., MARYLAND

Free format text: ASSIGNMENT OF ASSIGNOR'S INTEREST;ASSIGNOR:RUFF, MICHAEL R.;REEL/FRAME:066399/0235

Effective date: 20181031

FEPP Fee payment procedure

Free format text: ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: BIG.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

AS Assignment

Owner name: CREATIVE BIO-PEPTIDES, INC., MARYLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:RUFF, MICHAEL R.;REEL/FRAME:067597/0403

Effective date: 20240603

Owner name: CREATIVE BIO-PEPTIDES, INC., MARYLAND

Free format text: ASSIGNMENT OF ASSIGNOR'S INTEREST;ASSIGNOR:RUFF, MICHAEL R.;REEL/FRAME:067597/0403

Effective date: 20240603